한글목차

약제 요약

FDA는 18세 이상 천식 환자의 기관지 수축 치료 또는 예방, 천식 발작 위험 감소를 위해 AIRSUPRA(알부테롤, 부데소니드) 흡입용 에어로졸을 승인했으며, AIRSUPRA는 알부테롤과 부데소니드를 모두 포함하고 있습니다. 이 두 약제는 천식의 임상, 생리학 및 염증 지수에 대해 서로 다른 효과를 나타내는 두 가지 약물 계열(속효성 선택적 β2-adrenergic agonist와 합성 코르티코스테로이드)을 나타냅니다.

이 치료법은 근육을 이완시키고 폐 호흡기의 염증을 감소시켜 심각한 천식 발작의 위험을 줄여주며, 알부테롤 90mcg과 부데소니드 80mcg을 1회 2회(총 용량은 알부테롤 180mcg과 부데소니드 160mcg), 천식 증상에 따라 경구 흡입으로 투여합니다. 천식 증상에 따라 경구 흡입으로 투여합니다.

FDA는 2023년 1월에 승인했습니다.

주요 7 시장(미국, 독일, 프랑스, 이탈리아, 스페인, 영국, 일본)의 천식용 AIRSUPRA에 대해 조사분석했으며, 시장 규모 예측 및 작용기서, 용법과 용량, 연구개발 활동 등의 정보를 제공하고 있습니다.

목차

제1장 리포트 서론

제2장 천식에서 AIRSUPRA의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 규제 마일스톤
• 기타 개발 활동
• 제품의 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계의 새로운 치료법)

제5장 AIRSUPRA 시장 평가

• 천식 치료에서 AIRSUPRA 시장 전망
• 주요 7 시장의 분석
  • 주요 7 시장의 천식용 AIRSUPRA 시장 규모
• 시장의 분석 : 국가별
  • 미국의 천식용 AIRSUPRA 시장 규모
  • 독일의 천식용 AIRSUPRA 시장 규모
  • 영국의 천식용 AIRSUPRA 시장 규모

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

"AIRSUPRA Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about AIRSUPRA for Asthma in the seven major markets. A detailed picture of the AIRSUPRA for Asthma in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the AIRSUPRA for Asthma. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the AIRSUPRA market forecast analysis for Asthma in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Asthma.

Drug Summary:

FDA has approved AIRSUPRA (albuterol and budesonide) inhalation aerosol for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks in patients with asthma 18 years and older. AIRSUPRA contains both albuterol and budesonide. These drugs represent two classes of medications (a short-acting selective beta2-adrenergic agonist and a synthetic corticosteroid) that have different effects on clinical, physiological, and inflammatory indices of asthma.

The treatment works to relax the muscles and reduce inflammation in the lung airways to reduce the risk of severe asthma attacks. AIRSUPRA is given as two oral inhalations of a combination of albuterol 90 mcg and budesonide 80 mcg per inhalation (total dose albuterol 180 mcg and budesonide 160 mcg) as needed for asthma symptoms.

The FDA approved it in January 2023.

• Dosage and administration

The recommended dosage of AIRSUPRA is albuterol 180 mcg and budesonide 160 mcg (administered as two actuation of AIRSUPRA [albuterol/budesonide 90 mcg/80 mcg]) as needed for asthma symptoms by oral inhalation. Do not take more than six doses (12 inhalations) in 24 h.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the AIRSUPRA description, mechanism of action, dosage and administration, research and development activities in Asthma.
• Elaborated details on AIRSUPRA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the AIRSUPRA research and development activities in Asthma across the United States, Europe, and Japan.
• The report also covers the patents information with expiry timeline around AIRSUPRA.
• The report contains forecasted sales of AIRSUPRA for Asthma till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Asthma.
• The report also features the SWOT analysis with analyst views for AIRSUPRA in Asthma.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

AIRSUPRA Analytical Perspective by DelveInsight

• In-depth AIRSUPRA Market Assessment

This report provides a detailed market assessment of AIRSUPRA for Asthma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• AIRSUPRA Clinical Assessment

The report provides the clinical trials information of AIRSUPRA for Asthma covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Asthma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence AIRSUPRA dominance.
• Other emerging products for Asthma are expected to give tough market competition to AIRSUPRA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of AIRSUPRA in Asthma.
• Our in-depth analysis of the forecasted sales data of AIRSUPRA from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AIRSUPRA in Asthma.

Key Questions:

• What is the product type, route of administration and mechanism of action of AIRSUPRA?
• What is the clinical trial status of the study related to AIRSUPRA in Asthma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AIRSUPRA development?
• What are the key designations that have been granted to AIRSUPRA for Asthma?
• What is the forecasted market scenario of AIRSUPRA for Asthma?
• What are the forecasted sales of AIRSUPRA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to AIRSUPRA for Asthma?
• Which are the late-stage emerging therapies under development for the treatment of Asthma?

Table of Contents

1. Report Introduction

2. AIRSUPRA Overview in Asthma

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestones
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. AIRSUPRA Market Assessment

• 5.1. Market Outlook of AIRSUPRA in Asthma
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of AIRSUPRA in the 7MM for Asthma
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of AIRSUPRA in the United States for Asthma
  • 5.3.2. Market Size of AIRSUPRA in Germany for Asthma
  • 5.3.3. Market Size of AIRSUPRA in France for Asthma
  • 5.3.4. Market Size of AIRSUPRA in Italy for Asthma
  • 5.3.5. Market Size of AIRSUPRA in Spain for Asthma
  • 5.3.6. Market Size of AIRSUPRA in the United Kingdom for Asthma
  • 5.3.7. Market Size of AIRSUPRA in Japan for Asthma

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options